These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 2882047)

  • 1. The effects of somatostatin and SMS 201-995 on experimentally-induced pancreatitis and endotoxaemia in rats and on monocyte activity in patients with cirrhosis and portal hypertension.
    Jenkins SA; Baxter JN; Day DW; Al-Sumidaie AM; Leinster SJ; Shields R
    Klin Wochenschr; 1986; 64 Suppl 7():100-6. PubMed ID: 2882047
    [No Abstract]   [Full Text] [Related]  

  • 2. [Somatostatin and its analogs in the treatment of gastrointestinal and liver diseases].
    Feu F; Bosch J
    Gastroenterol Hepatol; 1996 Feb; 19(2):68-77. PubMed ID: 8616683
    [No Abstract]   [Full Text] [Related]  

  • 3. Antisecretory agents for prevention of post-ERCP pancreatitis: rationale for use and clinical results.
    Poon RT; Fan ST
    JOP; 2003 Jan; 4(1):33-40. PubMed ID: 12555014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of somatostatin and a long-acting somatostatin analogue on the prevention and treatment of experimentally induced acute pancreatitis in the rat.
    Baxter JN; Jenkins SA; Day DW; Roberts NB; Cowell DC; Mackie CR; Shields R
    Br J Surg; 1985 May; 72(5):382-5. PubMed ID: 2581647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Somatostatin, octreotide and portal hypertension].
    Silvain C; Besson I; Beauchant M
    Gastroenterol Clin Biol; 1994; 18(8-9):761-6. PubMed ID: 7875447
    [No Abstract]   [Full Text] [Related]  

  • 6. Antisecretory vs. antiproteasic drugs in the prevention of post-ERCP pancreatitis: the evidence-based medicine derived from a meta-analysis study.
    Andriulli A; Caruso N; Quitadamo M; Forlano R; Leandro G; Spirito F; De Maio G
    JOP; 2003 Jan; 4(1):41-8. PubMed ID: 12555015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attempts to reduce post-transplant pancreatitis in rats and dogs with the somatostatin analogue SMS 201-995.
    Spillenaar Bilgen EJ; Marquet RL; Baumgartner D; de Bruin RW; Lamberts SW; Jeekel J
    Transplant Proc; 1989 Feb; 21(1 Pt 3):2829-30. PubMed ID: 2468243
    [No Abstract]   [Full Text] [Related]  

  • 8. The effects of somatostatin and octreotide on experimental and human acute pancreatitis.
    Greenberg R; Haddad R; Kashtan H; Kaplan O
    J Lab Clin Med; 2000 Feb; 135(2):112-21. PubMed ID: 10695655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin and its analogues in G.I. tract, liver and pancreatic disorders.
    Dhar A; Chawla YK
    Trop Gastroenterol; 1995; 16(3):3-7. PubMed ID: 8838035
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of a somatostatin analogue (SMS 201-995) on hepatic and splenic reticulo-endothelial function in the rat.
    Baxter JN; Jenkins SA; Day DW; Shields R
    Br J Surg; 1985 Dec; 72(12):1005-8. PubMed ID: 2867801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of somatostatin and octreotide on liver microcirculation in an experimental mouse model of cirrhosis studied by intravital fluorescence microscopy.
    Vanheule E; Geerts AM; Reynaert H; Van Vlierberghe H; Geerts A; De Vos M; Colle I
    Liver Int; 2008 Jan; 28(1):107-16. PubMed ID: 18173562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of somatostatin and its analogues in the treatment of acute pancreatitis: clinical retrospective study].
    Citone G; Perri S; Nardi M; Maira E; Lotti R; Gabbrielli F; Antonellis M; Orsini S
    G Chir; 2001 Apr; 22(4):139-49. PubMed ID: 11370223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Somatostatin in the treatment of pancreatic diseases].
    Németh AM
    Orv Hetil; 2002 May; 143(19 Suppl):1099-108. PubMed ID: 12063869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatostatin analogue (SMS 201-995) but not somatostatin reduces indocyanine green clearance in the portal hypertensive rat.
    Kimchi N; Krepel Z; Ronen E; Bar-Meir E; Bruck R; Bar-Meir S
    Isr J Med Sci; 1993 Jan; 29(1):37-9. PubMed ID: 8095929
    [No Abstract]   [Full Text] [Related]  

  • 15. Somatostatin does not attenuate intestinal injury in dextran sodium sulphate-induced subacute colitis.
    van Bergeijk JD; van Meeteren ME; Tak CJ; van Dijk AP; Meijssen MA; Wilson JH; Zijlstra FJ
    Mediators Inflamm; 1998; 7(3):169-73. PubMed ID: 9705604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the somatostatin analogue octreotide on experimental pancreatitis in rats.
    Paran H; Klausner J; Siegal A; Graff E; Freund U; Kaplan O
    J Surg Res; 1996 May; 62(2):201-6. PubMed ID: 8632640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin analogue (SMS 201-995) in patients with gastrinomas.
    Vinik AI; Tsai S; Moattari AR; Cheung P
    Surgery; 1988 Nov; 104(5):834-42. PubMed ID: 2903562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection against duodenal ulceration by somatostatins.
    Palitzsch KD; Schuler H; Schwedes U; Usadel KH
    Klin Wochenschr; 1986; 64 Suppl 7():93-6. PubMed ID: 2882057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vapreotide acetate for the treatment of esophageal variceal bleeding.
    Calès P
    Expert Rev Gastroenterol Hepatol; 2008 Apr; 2(2):185-92. PubMed ID: 19072353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of octreotide (SMS 201-995) on experimentally induced pancreatitis with 50% ethyl alcohol in rats.
    Korun N; Yilmazlar T; Kaya E; Kutlay B
    Int Surg; 1994; 79(2):148-51. PubMed ID: 7523326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.